Earnings History of Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Nov 04 2016
The US-listed shares of Valeant surged to close up 33.7 per cent at $23.86 on Tuesday.
Valeant is also unloading businesses to slash a roughly $30 billion debt load.
Total volume traded so far was 186.2 million shares. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were trading -80.10% below from the 52-week high mark of $119.87 and +34.42% above from the 52-week bottom of $17.75. The company now has a Return on Equity (ROE) of -17.00% and a Return on Investment (ROI) of 3.70%. Its weekly performance is -12.96% while year to date (YTD) performance is -37.95%.
Pfizer Inc. (PFE) opened the session with a $30.99 price tag, later ranging from $30.36 to $31.04, the range at which the stock has traded at throughout the day. Analyst recommendation for this stock stands at 2.90. The estimated EPS for the current quarter is said to be $1.78. The firm issued the following statement regarding comments attributed to anonymous sources in a press report regarding its Gastroenterology business unit: "In accordance with its duties to shareholders and other stakeholders, management evaluates any transaction relating to core or non-core business units in accordance with the best interest of its shareholders and stakeholders".
Valeant Pharmaceuticals International Inc was sued on behalf of former shareholders in Sprout Pharmaceuticals Inc, which it bought a year ago for $1 billion, over its alleged failure to market the female libido pill Addyi successfully. However, its previous closing price was seen at $17.84.
The Bausch & Lomb acquisition gave Valeant well-known contact lenses, drugs to treat eye conditions such as glaucoma, pharmaceuticals, intraocular lenses and other eye surgery products. (NYSE:VRX) is performing -79.22%.
A look at performance overview of Valeant Pharmaceuticals International, Inc. depicts that Performance (Week) is -3.3 percent while Performance Month is -11.04%. But the stock's projection will be at $22 over that same time frame if the most conservative analyst's report is anything to go by. The difference in the numbers was $39.35M which caused a surprise factor of 1.60%. And immediately on the next day after earnings announcement, the stock inclined 25.43% and closed its trading session at $28.16. Even though Valeant has talked about GI as a core business and that it was focusing on divesting non-core assets, we do not believe Valeant has had as much of a core competency with GI as it has with dermatology and ophthalmology.
Barrick Gold Corporation (ABX) recently recorded -1.47 percent change and now at $18.14 is 164.6 percent away from its 52-week low and down -22.62 percent versus its peak.
Analysts' mean recommendation for Valeant Pharmaceuticals International, Inc.'s (VRX) stands at 2.90.